factually
Index/Topics/LM11A-31 Alzheimer Disease Trial

LM11A-31 Alzheimer Disease Trial

A 26-week phase 2a trial of LM11A-31 in people with mild-moderate Alzheimer disease, focusing on safety and tolerability, with statistically significant drug-placebo differences on several prespecified secondary and exploratory biomarker and imaging outcomes.

Fact-Checks

1 result
Jan 31, 2026
Most Viewed

What clinical trial evidence supports LM11A‑31 or other neuroprotective drug candidates for Alzheimer’s?

, a small‑molecule modulator of the p75 neurotrophin receptor (p75NTR), completed a randomized, double‑blind, placebo‑controlled phase 2a trial in 242 people with mild–moderate and met its prespecifie...